Oxidative phosphorylation inhibitors inhibit proliferation of endometriosis cells

Arvinder Kapur1, Jose M Ayuso2,3, Shujah Rehman4

  • 1Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Reproduction (Cambridge, England)
|April 17, 2023
PubMed

Insights

Inhibiting oxidative phosphorylation (OXPHOS) with agents like atovaquone shows promise for treating endometriosis. This approach targets endometriotic cell growth and migration, offering a potential new therapeutic strategy for millions worldwide.

Area of Science:

  • Biomedical research
  • Cell biology
  • Drug discovery

Background:

  • Endometriosis affects over 180 million women globally, with current treatments focused on symptom management rather than cures.
  • Novel therapeutic strategies are urgently needed to address this unmet medical need.

Purpose of the Study:

  • To investigate the potential of inhibiting oxidative phosphorylation (OXPHOS) as a novel treatment for endometriosis.
  • To evaluate the efficacy of OXPHOS inhibitors (curcumin, plumbagin, atovaquone) using a new organotypic organ-on-a-chip model.

Main Methods:

  • Utilized an organotypic organ-on-a-chip luminal model for endometriosis.
  • Tested OXPHOS inhibitors (curcumin, plumbagin, atovaquone) on the 12Z endometriosis cell line.
  • Assessed cellular proliferation, death, DNA damage (phospho-γH2Ax), mitochondrial respiration, cell migration, and metabolic changes (NAD(P)H/FAD redox ratio).

Main Results:

  • Curcumin, plumbagin, and atovaquone inhibited 12Z cell proliferation and induced cell death by targeting OXPHOS.
  • Compounds increased intracellular oxygen radicals, leading to DNA double-strand breaks.
  • Atovaquone demonstrated robust chemotoxic effects, inhibiting mitochondrial complexes I, II, and III.
  • Inhibition of cell migration and significant metabolic alterations were observed in the organ-on-a-chip model.

Conclusions:

  • Inhibiting oxidative phosphorylation is a viable novel therapeutic strategy for endometriosis.
  • Atovaquone, an anti-malarial drug, shows potential for repurposing in endometriosis treatment due to its efficacy.
  • The developed organ-on-a-chip model is effective for evaluating endometriosis therapies.

Related Concept Videos

Oogenesis02:07

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
17.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.6K